2025.03
Congratulations! We helped our client’s exosome product in obtaining FDA IND approval
Pantrone helped a biotech company in Taiwan to obtain the Investigational New Drug (IND) in of a genetically modified exosome in United States. The IND was granted by FDA within 30 days after submission. This is also the first US IND of exosome product in Taiwan. Pantrone created a record among all CROs in Taiwan again and helped our clients to achieve an important milestone again.
2023.09
Congratulations! We helped our client’s Car-T cell product in obtaining FDA IND approval.
Pantrone helped a leading cell therapy company in Taiwan to obtain Investigational New Drug (IND) of an allogeneic Chimeric Antigen Receptor T (Car-T) cell for treating solid tumors in United States. The IND was granted by FDA within 30 days after submission. This case is also the first US IND of allogeneic Car-T product in Taiwan. Pantrone created a record among all CROs in Taiwan and helped our clients to achieve an important milestone again.
2022.07
Congratulations! We helped our client’s stem cell product in obtaining FDA IND approval.
Pantrone helped a leading cell therapy company in Taiwan to obtain Investigational New Drug (IND) of Umbilical Cord Mesenchymal Stem Cell (UCMSC) therapy for Multiple Sclerosis (MS) in United States. The IND was granted by FDA within 30 days after submission. Once again, Pantrone helped our clients to achieve an important milestone.